Alkermes plc

NasdaqGS:ALKS Rapport sur les actions

Capitalisation boursière : US$4.6b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Alkermes Croissance future

Future contrôle des critères 1/6

Alkermes devrait augmenter ses bénéfices et son chiffre d'affaires de 1.4% et de 0.4% par an respectivement. Le BPA devrait croître de diminuer de 0.3% par an. Le rendement des capitaux propres devrait être 22.8% dans 3 ans.

Informations clés

1.4%

Taux de croissance des bénéfices

-0.3%

Taux de croissance du BPA

Biotechs croissance des bénéfices30.3%
Taux de croissance des recettes0.4%
Rendement futur des capitaux propres22.8%
Couverture par les analystes

Good

Dernière mise à jour03 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Alkermes: Fairly Valued After Post-Earnings Bump

Jul 28

Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Jul 26
Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

Jul 04
Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 17

Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

May 08
Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Apr 09

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Apr 08
Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet

Jan 26

Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Nov 01
Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Nov 01
Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?

Jul 15
Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?

There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding

Jun 07
There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding

Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?

Apr 10
Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Mar 20
Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Alkermes upgraded to neutral at BofA on improved risk/reward outlook

Oct 14

Alkermes holder Sarissa Capital says it may look to increase its stake

Oct 07

Alkermes: Nothing Stands Out As Interesting

Sep 26

Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Aug 29
Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Alkermes initiated at neutral at Piper Sandler as company in transition

Aug 16

Alkermes Q2 2022 Earnings Preview

Jul 26

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?

Jun 27
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?

Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

May 16
Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Alkermes: Turning The Tides Towards Profitability

Apr 16

Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Feb 07
Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:ALKS - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20261,56938557054512
12/31/20251,50934640949114
12/31/20241,51133441449814
6/30/20241,508386327374N/A
3/31/20241,726570394444N/A
12/31/20231,663519353401N/A
9/30/20231,591412254295N/A
6/30/20231,462300159196N/A
3/31/20231,121-9-59-22N/A
12/31/20221,112-33-1721N/A
9/30/20221,132-1291451N/A
6/30/20221,173-94102133N/A
3/31/20221,201-62140169N/A
12/31/20211,1747673102N/A
9/30/20211,129-92112138N/A
6/30/20211,100-6388115N/A
3/31/20211,044-954878N/A
12/31/20201,039-1114183N/A
9/30/20201,171-74-1158N/A
6/30/20201,162-126-5328N/A
3/31/20201,194-139-7810N/A
12/31/20191,171-197-1972N/A
9/30/20191,074-2011491N/A
6/30/20191,067-1831993N/A
3/31/20191,092-17374148N/A
12/31/20181,094-1393099N/A
9/30/20181,054-139575N/A
6/30/20181,023-141-561N/A
3/31/2018937-152N/A6N/A
12/31/2017903-158N/A19N/A
9/30/2017842-169N/A-9N/A
6/30/2017804-196N/A-14N/A
3/31/2017781-200N/A-20N/A
12/31/2016746-208N/A-64N/A
9/30/2016695-257N/A-69N/A
6/30/2016668-275N/A-113N/A
3/31/2016624-274N/A-100N/A
12/31/2015628-227N/A-40N/A
9/30/2015640-127N/A-29N/A
6/30/2015648-86N/A-7N/A
3/31/2015650-36N/A17N/A
12/31/2014619-30N/A11N/A
9/30/2014598-42N/A36N/A
6/30/2014578-10N/A85N/A
3/31/2014563-7N/A89N/A
12/31/201359621N/A148N/A
9/30/201357819N/A136N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ALKS ( 1.4% par an) est inférieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de ALKS ( 1.4% par an) devraient croître plus lentement que le marché US ( 15.1% par an).

Croissance élevée des bénéfices: Les bénéfices de ALKS devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ALKS ( 0.4% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ALKS ( 0.4% par an) devrait croître plus lentement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de ALKS devrait être élevé dans 3 ans ( 22.8 %)


Découvrir les entreprises en croissance